JP2012532091A - ラタノプロストのバイオアベイラビリティを向上させる方法 - Google Patents
ラタノプロストのバイオアベイラビリティを向上させる方法 Download PDFInfo
- Publication number
- JP2012532091A JP2012532091A JP2011551134A JP2011551134A JP2012532091A JP 2012532091 A JP2012532091 A JP 2012532091A JP 2011551134 A JP2011551134 A JP 2011551134A JP 2011551134 A JP2011551134 A JP 2011551134A JP 2012532091 A JP2012532091 A JP 2012532091A
- Authority
- JP
- Japan
- Prior art keywords
- latanoprost
- eye drop
- aqueous
- drop composition
- organic amine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 title claims abstract description 127
- 229960001160 latanoprost Drugs 0.000 title claims abstract description 105
- 239000000203 mixture Substances 0.000 claims abstract description 83
- 239000003889 eye drop Substances 0.000 claims abstract description 55
- 150000001412 amines Chemical class 0.000 claims abstract description 39
- 238000000034 method Methods 0.000 claims abstract description 21
- 208000010412 Glaucoma Diseases 0.000 claims abstract description 15
- 206010030043 Ocular hypertension Diseases 0.000 claims abstract description 12
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 31
- 229960000281 trometamol Drugs 0.000 claims description 31
- -1 polyethylene Polymers 0.000 claims description 21
- 239000003755 preservative agent Substances 0.000 claims description 20
- 239000004698 Polyethylene Substances 0.000 claims description 16
- 229920000573 polyethylene Polymers 0.000 claims description 16
- 230000002335 preservative effect Effects 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 239000002562 thickening agent Substances 0.000 claims description 9
- 239000012530 fluid Substances 0.000 claims description 8
- 239000012611 container material Substances 0.000 claims description 6
- 239000002736 nonionic surfactant Substances 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 5
- 239000002997 ophthalmic solution Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000004410 intraocular pressure Effects 0.000 description 18
- 241000283973 Oryctolagus cuniculus Species 0.000 description 16
- 229940002639 xalatan Drugs 0.000 description 16
- 239000012085 test solution Substances 0.000 description 15
- 210000001742 aqueous humor Anatomy 0.000 description 11
- 150000003180 prostaglandins Chemical class 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000035515 penetration Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 229960000686 benzalkonium chloride Drugs 0.000 description 7
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229960004458 tafluprost Drugs 0.000 description 5
- WSNODXPBBALQOF-VEJSHDCNSA-N tafluprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COC1=CC=CC=C1 WSNODXPBBALQOF-VEJSHDCNSA-N 0.000 description 5
- LSIXBBPOJBJQHN-UHFFFAOYSA-N 2,3-Dimethylbicyclo[2.2.1]hept-2-ene Chemical compound C1CC2C(C)=C(C)C1C2 LSIXBBPOJBJQHN-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229940012356 eye drops Drugs 0.000 description 4
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 4
- 239000003002 pH adjusting agent Substances 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000011200 topical administration Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229950008882 polysorbate Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241000282320 Panthera leo Species 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000004397 blinking Effects 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 238000010101 extrusion blow moulding Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000010102 injection blow moulding Methods 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000012088 reference solution Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- HNPFPERDNWXAGS-LZCJLJQNSA-N (e)-7-[3,5-dihydroxy-2-(3-hydroxy-5-phenylpentyl)cyclopentyl]hept-5-enoic acid Chemical compound C=1C=CC=CC=1CCC(O)CCC1C(O)CC(O)C1C\C=C\CCCC(O)=O HNPFPERDNWXAGS-LZCJLJQNSA-N 0.000 description 1
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- OCYJXSUPZMNXEN-UHFFFAOYSA-N 2-amino-1-(4-nitrophenyl)propane-1,3-diol Chemical compound OCC(N)C(O)C1=CC=C([N+]([O-])=O)C=C1 OCYJXSUPZMNXEN-UHFFFAOYSA-N 0.000 description 1
- NXYQWAUYFQDQFP-UHFFFAOYSA-N 2h-oxazine;pyridine-2-carboxylic acid Chemical compound N1OC=CC=C1.OC(=O)C1=CC=CC=N1 NXYQWAUYFQDQFP-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101100256637 Drosophila melanogaster senju gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 208000035620 Eye penetration Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229920002292 Nylon 6 Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N benzyl-alpha-carboxylic acid Natural products OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 238000005429 filling process Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229960004811 pemirolast potassium Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- NMMVKSMGBDRONO-UHFFFAOYSA-N potassium;9-methyl-3-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)pyrido[1,2-a]pyrimidin-4-one Chemical compound [K+].CC1=CC=CN(C2=O)C1=NC=C2C1=NN=N[N-]1 NMMVKSMGBDRONO-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 description 1
- 229960002368 travoprost Drugs 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 229950008081 unoprostone isopropyl Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
本発明はまた、ラタノプロストを含む水性点眼薬組成物であって、ラタノプロストの眼におけるバイオアベイラビリティは、有機アミンを添加することによって向上する、水性点眼薬組成物に向けられる。
本発明に係るラタノプロストを含む水性点眼薬組成物では、実質的にポリエチレンからなる単位用量容器もしくは流体ディスペンサの中に、または、実質的にポリエチレンからなる容器材料と接触させて、ラタノプロストを0.0025〜0.005%(w/v)、トロメタモールを0.1〜1%(w/v)含み、眼科用液剤で従来から用いられている緩衝剤、pH調整剤、等張化剤および増粘剤を任意に含み、実質的に防腐剤を含んでいないことが好ましい。
ラタノプロストが均質にかつ安定的に水溶液に溶解している限り、ラタノプロストおよび有機アミン以外の成分は特に限定されないであろう。しかしながら、単回投与の形態で用いられるように安定性のあるバイオアベイラブルな処方を提供するために本発明の水性点眼薬組成物では非イオン界面活性剤(ポリソルベート、クレモホールなど)または防腐剤が不要であることは注目に値する。
(1) 試液A
ラタノプロスト/トロメタモール比:0.013(ラタノプロスト濃度:0.005%)
(2) 試液B
ラタノプロスト/トロメタモール比:0.017(ラタノプロスト濃度:0.005%)
(3) 試液C
ラタノプロスト/トロメタモール比:0.017(ラタノプロスト濃度:0.005%)
(4) 試液D
ラタノプロスト/トロメタモール比:0.029(ラタノプロスト濃度:0.0035%)
各時点でウサギを犠牲にし(時点当たりの治療当たり4匹の動物)、眼房水サンプルを取得した。ラタノプロスト酸の濃度は、HPLC/MS法を用いて測定した。試液A、B、CおよびDの結果をそれぞれ図1A、図1B、図1Cおよび図1Dに示す。
(1) 試液E
ラタノプロスト/トロメタモール比:0.020(キサラタン中のラタノプロスト濃度と同じラタノプロスト濃度)
(2) 試液F
ラタノプロスト/トロメタモール比:0.029(ラタノプロスト濃度:キサラタンの70%)
試験当たり6〜12匹の動物を用いた。投与後0時間および2時間、4時間、6時間および8時間(またはさらに10時間)で投与する前に、IOPを測定した。測定は、TonoLabリバウンドトノメータで行なった。
Claims (12)
- ラタノプロストを含有する水性点眼薬組成物に有機アミンを添加することによって、前記点眼薬組成物のラタノプロストの眼におけるバイオアベイラビリティを向上させる方法。
- 前記有機アミンは、ヒドロキシ基を有する有機アミンである、請求項1に記載の方法。
- ヒドロキシ基を有する前記有機アミンは、トロメタモールである、請求項2に記載の方法。
- 前記水性点眼薬組成物は、実質的に防腐剤を含有していない、請求項1に記載の方法。
- 前記水性点眼薬組成物は、増粘剤を含有している、請求項1に記載の方法。
- ラタノプロストの眼におけるバイオアベイラビリティが、有機アミンを添加することによって向上された、ラタノプロストを含む水性点眼薬組成物。
- 前記有機アミンが、ヒドロキシ基を有する有機アミンである、請求項6に記載の水性点眼薬組成物。
- ヒドロキシ基を有する前記有機アミンが、トロメタモールである、請求項7に記載の水性点眼薬組成物。
- 防腐剤または非イオン界面活性剤を実質的に含有していない、請求項7に記載の水性点眼薬組成物。
- 粘性促進剤をさらに含む、請求項6に記載の水性点眼薬組成物。
- 実質的にポリエチレンからなる単位用量容器もしくは流体ディスペンサの中に、または、実質的にポリエチレンからなる容器材料と接触させて、ラタノプロストを0.0025〜0.005%(w/v)、トロメタモールを0.1〜1%(w/v)含み、眼科用液剤で従来から用いられている緩衝剤、pH調整剤、等張化剤および増粘剤を任意に含み、実質的に防腐剤を含んでいない、請求項6に記載の水性点眼薬組成物。
- ラタノプロストを含む有効量の水性点眼薬組成物を、高眼圧症および緑内障の治療を必要とする被験者に投与することによって、高眼圧症および緑内障を治療する方法であって、ラタノプロストの眼におけるバイオアベイラビリティは、有機アミンを添加することによって向上する、方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09397519.1 | 2009-06-30 | ||
EP09397519A EP2269575A1 (en) | 2009-06-30 | 2009-06-30 | Method for improving bioavailability of latanoprost |
PCT/JP2010/004179 WO2011001634A1 (en) | 2009-06-30 | 2010-06-23 | Method for improving bioavailability of latanoprost |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012532091A true JP2012532091A (ja) | 2012-12-13 |
JP5695580B2 JP5695580B2 (ja) | 2015-04-08 |
Family
ID=41137869
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011551134A Expired - Fee Related JP5695580B2 (ja) | 2009-06-30 | 2010-06-23 | ラタノプロストのバイオアベイラビリティを向上させる方法 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20120107376A1 (ja) |
EP (2) | EP2269575A1 (ja) |
JP (1) | JP5695580B2 (ja) |
KR (1) | KR20120095341A (ja) |
CN (1) | CN102802633B (ja) |
CA (1) | CA2766269C (ja) |
EA (1) | EA022390B1 (ja) |
HK (1) | HK1172849A1 (ja) |
MY (1) | MY157434A (ja) |
SG (1) | SG176800A1 (ja) |
UA (1) | UA107466C2 (ja) |
WO (1) | WO2011001634A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GR1008483B (el) * | 2013-12-23 | 2015-05-12 | Rafarm Α.Ε.Β.Ε., | Οφθαλμικη φαρμακευτικη συνθεση και μεθοδος για την παρασκευη αυτης |
WO2018033854A1 (en) | 2016-08-15 | 2018-02-22 | Santen Pharmaceutical Co., Ltd. | Ophthalmic composition and a method for treating ocular hypertension and glaucoma |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006049250A1 (ja) * | 2004-11-05 | 2006-05-11 | Senju Pharmaceutical Co., Ltd. | 眼内移行性促進水性点眼剤 |
WO2007015510A1 (ja) * | 2005-08-02 | 2007-02-08 | Santen Pharmaceutical Co., Ltd. | 熱的に不安定な薬物の分解抑制方法 |
WO2008096804A1 (ja) * | 2007-02-07 | 2008-08-14 | Teika Pharmaceutical Co., Ltd. | ラタノプロスト含有点眼剤 |
JP2009040749A (ja) * | 2007-08-10 | 2009-02-26 | Kaken Pharmaceut Co Ltd | ラタノプロスト点眼剤 |
JP2009518395A (ja) * | 2005-12-09 | 2009-05-07 | テバ ファーマシューティカル インダストリーズ リミティド | 難溶性化合物の水性分散物および溶液ならびにそれらの調製方法 |
JP2010533221A (ja) * | 2007-07-11 | 2010-10-21 | オフサルモファーマ・アクチェンゲゼルシャフト | プロスタグランジン誘導体と1置換荷電ベータシクロデキストリンとの複合体 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5040706A (en) * | 1989-03-17 | 1991-08-20 | Insite Vision, Inc. | Liquid droplet dispensing apparatus |
JPH03146881A (ja) | 1989-11-01 | 1991-06-21 | Fanuc Ltd | プリント基板の保持フレームの着脱構造 |
JPH0689576B2 (ja) | 1989-12-30 | 1994-11-09 | 株式会社第一ホーム | 根太固定装置 |
JPH042364A (ja) | 1990-04-19 | 1992-01-07 | Olympus Optical Co Ltd | 瘻孔形成管 |
DE4027320C2 (de) | 1990-08-29 | 1993-09-30 | Ursapharm Arzneimittel Gmbh | Fluid-Abgabeeinrichtung für keimfreies Fluid |
JP3659801B2 (ja) | 1998-04-21 | 2005-06-15 | キッセイ薬品工業株式会社 | トラニラスト水溶液製剤 |
ES2357551T3 (es) | 2000-09-13 | 2011-04-27 | Santen Pharmaceutical Co., Ltd. | Colirio. |
US20030055052A1 (en) | 2000-11-10 | 2003-03-20 | Stefan Peters | FAP-activated anti-tumor compounds |
TW586946B (en) | 2000-12-22 | 2004-05-11 | Novartis Ag | Process to improve stability |
US7074827B2 (en) | 2002-10-24 | 2006-07-11 | Sucampo Ag (Usa) Inc. | Method for treating ocular hypertension and glaucoma |
JP2006187602A (ja) | 2004-12-09 | 2006-07-20 | Santen Pharmaceut Co Ltd | 分子内にフッ素原子を有するプロスタグランジン含有製品 |
TWI465236B (zh) | 2007-03-13 | 2014-12-21 | 參天製藥股份有限公司 | 含有吡諾克辛之懸浮型水性液劑 |
-
2009
- 2009-06-30 EP EP09397519A patent/EP2269575A1/en not_active Withdrawn
-
2010
- 2010-06-23 KR KR1020127001350A patent/KR20120095341A/ko active Search and Examination
- 2010-06-23 SG SG2011091741A patent/SG176800A1/en unknown
- 2010-06-23 US US13/381,631 patent/US20120107376A1/en not_active Abandoned
- 2010-06-23 EP EP10793808.6A patent/EP2448589A4/en not_active Withdrawn
- 2010-06-23 UA UAA201200886A patent/UA107466C2/uk unknown
- 2010-06-23 MY MYPI2011006155A patent/MY157434A/en unknown
- 2010-06-23 JP JP2011551134A patent/JP5695580B2/ja not_active Expired - Fee Related
- 2010-06-23 EA EA201270097A patent/EA022390B1/ru not_active IP Right Cessation
- 2010-06-23 CN CN201080028960.9A patent/CN102802633B/zh not_active Expired - Fee Related
- 2010-06-23 WO PCT/JP2010/004179 patent/WO2011001634A1/en active Application Filing
- 2010-06-23 CA CA2766269A patent/CA2766269C/en not_active Expired - Fee Related
-
2013
- 2013-01-07 HK HK13100192.1A patent/HK1172849A1/zh not_active IP Right Cessation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006049250A1 (ja) * | 2004-11-05 | 2006-05-11 | Senju Pharmaceutical Co., Ltd. | 眼内移行性促進水性点眼剤 |
WO2007015510A1 (ja) * | 2005-08-02 | 2007-02-08 | Santen Pharmaceutical Co., Ltd. | 熱的に不安定な薬物の分解抑制方法 |
JP2009518395A (ja) * | 2005-12-09 | 2009-05-07 | テバ ファーマシューティカル インダストリーズ リミティド | 難溶性化合物の水性分散物および溶液ならびにそれらの調製方法 |
WO2008096804A1 (ja) * | 2007-02-07 | 2008-08-14 | Teika Pharmaceutical Co., Ltd. | ラタノプロスト含有点眼剤 |
JP2010533221A (ja) * | 2007-07-11 | 2010-10-21 | オフサルモファーマ・アクチェンゲゼルシャフト | プロスタグランジン誘導体と1置換荷電ベータシクロデキストリンとの複合体 |
JP2009040749A (ja) * | 2007-08-10 | 2009-02-26 | Kaken Pharmaceut Co Ltd | ラタノプロスト点眼剤 |
Also Published As
Publication number | Publication date |
---|---|
US20120107376A1 (en) | 2012-05-03 |
MY157434A (en) | 2016-06-15 |
HK1172849A1 (zh) | 2013-05-03 |
EP2448589A1 (en) | 2012-05-09 |
EA022390B1 (ru) | 2015-12-30 |
KR20120095341A (ko) | 2012-08-28 |
UA107466C2 (uk) | 2015-01-12 |
CN102802633B (zh) | 2016-01-20 |
JP5695580B2 (ja) | 2015-04-08 |
EA201270097A1 (ru) | 2012-05-30 |
SG176800A1 (en) | 2012-01-30 |
CN102802633A (zh) | 2012-11-28 |
CA2766269C (en) | 2018-04-03 |
EP2269575A1 (en) | 2011-01-05 |
CA2766269A1 (en) | 2011-01-06 |
WO2011001634A1 (en) | 2011-01-06 |
EP2448589A4 (en) | 2013-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6889789B2 (ja) | 高眼圧症及び緑内障を治療するための方法及び組成物 | |
JP5695580B2 (ja) | ラタノプロストのバイオアベイラビリティを向上させる方法 | |
EP3593788B1 (en) | Ophthalmic compositions containing a nitric oxide releasing prostamide | |
JP2020172486A (ja) | エピナスチン又はその塩を含有する水性医薬組成物 | |
JP2008120764A (ja) | プロスタグランジン水性点眼剤 | |
WO2021210646A1 (ja) | エピナスチン又はその塩を含有する水性組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130430 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140527 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140723 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150113 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150206 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5695580 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |